Pediatric fever of uncertain source: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
|||
(24 intermediate revisions by 5 users not shown) | |||
Line 2: | Line 2: | ||
*Medicine is an art as well as science, practice clinical judgment when using guidelines | *Medicine is an art as well as science, practice clinical judgment when using guidelines | ||
*Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d | *Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d | ||
*Fever accounts for 30% of pediatric visits | |||
*Children <3 mo are immunocompromised- poor opsonization, poor IgG response to encapsulated bacteria, macrophage and neutrophil dysfunction, bone marrow insufficiency | |||
*Serious bacterial illness (SBI) includes UTI, meningitis, pneumonia, bacteremia | |||
{| class="wikitable" | {| class="wikitable" | ||
Line 24: | Line 27: | ||
===Concomitant RSV or Infulenza Infection=== | ===Concomitant RSV or Infulenza Infection=== | ||
*Relatively high coincidence of bronchiolitis w/ UTI, and of enterovirus and paraflu w/ UTI and bacteremia | |||
*In RSV+ (by PCR) neonates aged 0-28 days, 6.1% had UTIs and 3.7% were bactremic; there was no difference in rates of SBI between RSV+ and RSV- neonates in a large prospective multicenter study entailing 1,248 children<ref>Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.</ref> | *In RSV+ (by PCR) neonates aged 0-28 days, 6.1% had UTIs and 3.7% were bactremic; there was no difference in rates of SBI between RSV+ and RSV- neonates in a large prospective multicenter study entailing 1,248 children<ref>Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.</ref> | ||
*RSV+ infants aged 29-60 days, the SBI rate was 5.5%, all of which were UTIs | *RSV+ infants aged 29-60 days, the SBI rate was 5.5%, all of which were UTIs | ||
Line 31: | Line 35: | ||
{{Pediatric fever DDX}} | {{Pediatric fever DDX}} | ||
== | ==Evaluation & Management== | ||
[[File:Pediatric Fever2.png|thumb|Algorithm for the evaluation of pediatric fever]] | [[File:Pediatric Fever2.png|thumb|Algorithm for the evaluation of pediatric fever]] | ||
===0-28dy === | ===0-28dy=== | ||
*SBI in ill-appearing febrile neonate as high as 20% | |||
*SBI in well-appearing febrile neonate as high as 5% | |||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
Line 42: | Line 49: | ||
| '''Comments''' | | '''Comments''' | ||
|- | |- | ||
| ''' | | '''Temperature ≥38°''' | ||
'''Toxic or Well''' | '''Toxic or Well''' | ||
| | | | ||
*CBC | *CBC | ||
*Blood cultures | *Blood cultures | ||
* | *[[Urinalysis]], Urine culture | ||
*LP-CSF | *LP-CSF | ||
*CXR | *[[CXR]] | ||
*+/- Stool studies (if diarrhea) | *+/- Stool studies (if diarrhea) | ||
| | | | ||
Line 60: | Line 67: | ||
{{Pediatric fever acyclovir indications}} | {{Pediatric fever acyclovir indications}} | ||
Note: | |||
*CXR is optional if no resp sx and another source identified | |||
*LP is necessary even if another source identified due to immature blood-brain barrier | |||
*Do not give ceftriaxone to children <28d as may cause hyperbilirubinemia | |||
===28dy-90dy<ref> Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.</ref>=== | ===28dy-90dy<ref> Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.</ref>=== | ||
Line 73: | Line 85: | ||
*CBC | *CBC | ||
*Blood cultures | *Blood cultures | ||
* | *[[Urinalysis]], Urine culture | ||
*[[LP]]-CSF | *[[LP]]-CSF | ||
*+/- CXR | *+/- CXR | ||
Line 87: | Line 99: | ||
*CBC | *CBC | ||
*Blood cultures | *Blood cultures | ||
* | *[[Urinalysis]], urine culture | ||
*+/- [[LP]]-CSF (must do before giving antibiotics) | *+/- [[LP]]-CSF (must do before giving antibiotics) | ||
*+/- CXR | *+/- CXR | ||
Line 102: | Line 114: | ||
{{Pediatric fever acyclovir indications}} | {{Pediatric fever acyclovir indications}} | ||
===90dy-36mo<ref>Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.</ref> === | ===90dy-36mo<ref>Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.</ref>=== | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
Line 114: | Line 126: | ||
*CBC | *CBC | ||
*Blood cultures | *Blood cultures | ||
* | *[[Urinalysis]], urine culture | ||
*[[LP]]-CSF | *[[LP]]-CSF | ||
*CXR^ | *[[CXR]]^ | ||
| | | | ||
{{Pediatric fever antibiotics 90dy-36mo}} | {{Pediatric fever antibiotics 90dy-36mo}} | ||
Line 122: | Line 134: | ||
|- | |- | ||
| '''T≥39°C + Well + Non-complete [[Prevnar]]''' | | '''T≥39°C + Well + Non-complete [[Prevnar]]''' | ||
(No [[Prevnar]] or <4 | (No [[Prevnar]] or <4 weeks post 1st [[Prevnar]] dose) | ||
| | | | ||
* | *[[Urinalysis]], Urine culture | ||
*CBC | *CBC | ||
*+/- CXR | *+/- CXR | ||
| If WBC(+): | | If WBC(+): | ||
*[[Ceftriaxone]] 50mg-100mg/kg (also then consider [[ | *[[Ceftriaxone]] 50mg-100mg/kg (also then consider [[blood culture]] and [[LP]], especially in <6mo old) | ||
| Outpatient (24 hour follow-up) | | Outpatient (24 hour follow-up) | ||
|- | |- | ||
| '''T≥39°C + Well + [[Prevnar]]''' | | '''T≥39°C + Well + [[Prevnar]]''' | ||
(2 [[Prevnar]] or ≥4 | (2 [[Prevnar]] or ≥4 weeks post 1st [[Prevnar]] dose) | ||
| | | | ||
*Urine workup (UA, | *Urine workup (UA, urine culture) for: | ||
**Circumcised males <6 months | **Circumcised males <6 months | ||
**Uncircumcised males <12 months | **Uncircumcised males <12 months | ||
Line 149: | Line 161: | ||
|} | |} | ||
{{Pediatric fever CXR indications}} | {{Pediatric fever CXR indications}} | ||
*Non-UTI SBI incidence of <.4% in children >6 mo | |||
==Low Risk Lab Criteria== | ==Low Risk Lab Criteria== | ||
Line 159: | Line 173: | ||
*Neg Nitrate and Leukocyte esterase | *Neg Nitrate and Leukocyte esterase | ||
*WBC <10/high powered field | *WBC <10/high powered field | ||
===CSF=== | ===CSF=== | ||
====0-28 days==== | ====0-28 days==== | ||
Line 167: | Line 180: | ||
*WBC 0-7/mm<sup>3</sup> | *WBC 0-7/mm<sup>3</sup> | ||
*Protein: 15-25mg/dL | *Protein: 15-25mg/dL | ||
===Low Risk by Step-By-Step Approach<ref>Gomez B, Mintegi S, Bressan S, et al. Validation of the “Step-by-Step” Approach in the Management of Young Febrile Infants. Pediatrics. 2016;138(2):e20154381</ref>=== | |||
''Study validated against Rocheter criteria and Lab-score for identifying low risk for invasive bacterial infections (IBI), with '''''NPV ~98%''''' | |||
*Well appearing | |||
*Age > 21 days | |||
*No leukocyturia | |||
*Procalcitonin < 0.5 ng/mL | |||
*ANC < 10,000/mm3 | |||
*CRP < 20 mg/L | |||
====Low Risk Management<ref>Mintegi S, Gomez B, Martinez-Virumbrales L, et al. Outpatient management of selected young febrile infants without antibiotics. Arch Dis Child. 2016 Jul 28. pii: archdischild-2016-310600. doi: 10.1136/archdischild-2016-310600.</ref>==== | |||
*Offer no LP, no antibiotics, 24 hrs observation | |||
*Plan for prompt follow-up | |||
==Symptomatic Managment== | ==Symptomatic Managment== |
Revision as of 17:04, 20 June 2019
Background
- Medicine is an art as well as science, practice clinical judgment when using guidelines
- Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d
- Fever accounts for 30% of pediatric visits
- Children <3 mo are immunocompromised- poor opsonization, poor IgG response to encapsulated bacteria, macrophage and neutrophil dysfunction, bone marrow insufficiency
- Serious bacterial illness (SBI) includes UTI, meningitis, pneumonia, bacteremia
Age | 0-14 days | 14-28 days | 28-60 days (pre vaccine) | 28-60 days (post vaccine) | 60-90 days | > 90 days |
Meningitis/SBI Prevalence | 1/10 | 1/20 | 1/100 | 1/1000 | 1/1000-10,000 | > 1/10,000 |
Facts and Figures
From ACEP's Clinical Policy on Pediatric Fevers[1]
- 7% of patients < 2 years old with fever have pneumonia, however the etiology (viral/bacterial) or even the presence of pneumonia has low inter-observer reliability even among pediatric radiologists
- 4% Prevalence of UTI with common other sources of fever (OM, viral URI, et cetera)
- 1.5-2% background prevalence of asymptomatic bacteruria in healthy afebrile controls
- 0.3% Rate of occult bactremia with healthy, well-appearing child who has a fever 2-24 months
- 0.3% of previously well children aged 3-36 months who have a fever without a source will develop significant sequelae, 0.03% will develop sepsis or meningitis
Concomitant RSV or Infulenza Infection
- Relatively high coincidence of bronchiolitis w/ UTI, and of enterovirus and paraflu w/ UTI and bacteremia
- In RSV+ (by PCR) neonates aged 0-28 days, 6.1% had UTIs and 3.7% were bactremic; there was no difference in rates of SBI between RSV+ and RSV- neonates in a large prospective multicenter study entailing 1,248 children[2]
- RSV+ infants aged 29-60 days, the SBI rate was 5.5%, all of which were UTIs
- Influenza+, low risk of bacterial illness
Differential Diagnosis
Pediatric fever
- Upper respiratory infection (URI)
- UTI
- Sepsis
- Meningitis
- Febrile seizure
- Pneumonia
- Acute otitis media
- Whooping cough
- Unclear source
- Kawasaki disease
- Neonatal HSV
- Specific virus
Evaluation & Management
0-28dy
- SBI in ill-appearing febrile neonate as high as 20%
- SBI in well-appearing febrile neonate as high as 5%
Child Appearance | Work Up | Treatment | Disposition & Follow-up | Comments |
Temperature ≥38°
Toxic or Well |
|
|
Admit | SBI incidence
|
^Acyclovir if:
Note:
- CXR is optional if no resp sx and another source identified
- LP is necessary even if another source identified due to immature blood-brain barrier
- Do not give ceftriaxone to children <28d as may cause hyperbilirubinemia
28dy-90dy[3]
Appearance | Work Up | Treatment | Disposition & Follow-Up |
Temp≥38° + Toxic |
|
|
Admit |
Temp≥°38 + Well |
|
|
Workup(+): Antibiotics and admit
Workup(-): ?antibiotics; home with 24 follow-up |
^^Can use ceftriaxone 50-100mg/kg, but concern for bilirubin displacement
- Consider CXR for:
- Respiratory symptoms
- Fever >48 hrs
- Tachypnea
- Hypoxia
^Acyclovir if:
90dy-36mo[4]
Appearance | Work Up | Treatment | Disposition & Follow-Up |
T≥38° + Toxic |
|
|
Admit |
T≥39°C + Well + Non-complete Prevnar |
|
If WBC(+):
|
Outpatient (24 hour follow-up) |
T≥39°C + Well + Prevnar |
|
Treat cystitis or pneumonia if postitive | Outpatient (48hour follow up) |
T≥38-38.9°C + Well | Consider UA, CXR based on symptoms, etc | Treat cystitis or pneumonia if positive | Outpatient (48-72 hour follow-up)[5] |
- Consider CXR for:
- Respiratory symptoms
- Fever >48 hrs
- Tachypnea
- Hypoxia
- Non-UTI SBI incidence of <.4% in children >6 mo
Low Risk Lab Criteria
If low-risk criteria below not met, then perform the LP (if not done) and admit for inpatient antibiotics[6][7]
CBC
- WBC 5-15 /mm3
- Absolute Band count <1500 /mm3
Urinalysis
- Clear
- Neg Nitrate and Leukocyte esterase
- WBC <10/high powered field
CSF
0-28 days
- WBC: 0-22/mm3
- Protein: <100mg/dL
>29 days
- WBC 0-7/mm3
- Protein: 15-25mg/dL
Low Risk by Step-By-Step Approach[8]
Study validated against Rocheter criteria and Lab-score for identifying low risk for invasive bacterial infections (IBI), with NPV ~98%
- Well appearing
- Age > 21 days
- No leukocyturia
- Procalcitonin < 0.5 ng/mL
- ANC < 10,000/mm3
- CRP < 20 mg/L
Low Risk Management[9]
- Offer no LP, no antibiotics, 24 hrs observation
- Plan for prompt follow-up
Symptomatic Managment
Acetaminophen Pediatric Dosing Chart
Weight (kg) | Weight (lbs) | Age | Dosage (mg) |
3-4 | 6-11 | 0-3 mo | 40 |
5-7 | 12-17 | 4-11 mo | 80 |
8-10 | 18-23 | 1-2 y | 120 |
11-15 | 24-35 | 2-3 y | 160 |
16-21 | 36-47 | 4-5 y | 240 |
22-26 | 48-59 | 6-8 y | 320 |
27-32 | 60-71 | 9-10 y | 400 |
33-43 | 72-95 | 11 y | 480 |
- Dosage can be given q6 hours
See Also
- Acute fever
- Fever of unknown origin (peds)
- Urinary tract infection (peds)
- Sepsis (peds)
- Meningitis (peds)
- Febrile seizure
External Links
References
- ↑ Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545
- ↑ Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.
- ↑ Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.
- ↑ Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.
- ↑ Baker, M.D., Bello, L.M., & Avner, J.R. (1993). Outpatient management without antibiotics of fever in selected infants. New England Jouranl of Medicine, 329(20), 1437-1441.
- ↑ Smitherman, H.F. & Macias, C.G. (2014). Evaluation and management of fever in the neonate and young infant (less than three months of age) [Electronic Version]. UpToDate,Teach, S.J., Kaplan, SL, Wiley, JF.
- ↑ Dagan, R. Sofer, S., Phillip, M., & Shachak, E. (1988). Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serous bacterial infections. Journal of Pediatrics, 112(3), 355-360.
- ↑ Gomez B, Mintegi S, Bressan S, et al. Validation of the “Step-by-Step” Approach in the Management of Young Febrile Infants. Pediatrics. 2016;138(2):e20154381
- ↑ Mintegi S, Gomez B, Martinez-Virumbrales L, et al. Outpatient management of selected young febrile infants without antibiotics. Arch Dis Child. 2016 Jul 28. pii: archdischild-2016-310600. doi: 10.1136/archdischild-2016-310600.